120 related articles for article (PubMed ID: 17323628)
1. Novel treatment of a rare genetic bone disease.
McMahon MS
Orthopedics; 2007 Feb; 30(2):91. PubMed ID: 17323628
[No Abstract] [Full Text] [Related]
2. Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.
Yoshitaka T; Ishida S; Mukai T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014; 29(5):1170-82. PubMed ID: 24978678
[TBL] [Abstract][Full Text] [Related]
3. Jawing about TNF: new hope for cherubism.
Novack DV; Faccio R
Cell; 2007 Jan; 128(1):15-7. PubMed ID: 17218248
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor necrosis factor treatment in cherubism--clinical, radiological and histological findings in two children.
Hero M; Suomalainen A; Hagström J; Stoor P; Kontio R; Alapulli H; Arte S; Toiviainen-Salo S; Lahdenne P; Mäkitie O
Bone; 2013 Jan; 52(1):347-53. PubMed ID: 23069372
[TBL] [Abstract][Full Text] [Related]
5. Cherubism Study Results May Apply to Common Inflammatory Bone Diseases.
Dent Today; 2015 May; 34(5):54. PubMed ID: 26473261
[No Abstract] [Full Text] [Related]
6. [Molecular and Cellular Pathogenesis of Cherubism].
Ueki Y
Clin Calcium; 2016 Jun; 26(6):918-26. PubMed ID: 27230848
[TBL] [Abstract][Full Text] [Related]
7. Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism.
Levaot N; Voytyuk O; Dimitriou I; Sircoulomb F; Chandrakumar A; Deckert M; Krzyzanowski PM; Scotter A; Gu S; Janmohamed S; Cong F; Simoncic PD; Ueki Y; La Rose J; Rottapel R
Cell; 2011 Dec; 147(6):1324-39. PubMed ID: 22153076
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation.
Lietman SA; Kalinchinko N; Deng X; Kohanski R; Levine MA
Hum Mutat; 2006 Jul; 27(7):717-8. PubMed ID: 16786512
[TBL] [Abstract][Full Text] [Related]
9. [Gene mutation and expression of SH-3BP-2 in cherubism].
Li YW; Meng XM; Yu SF; Gao P
Zhonghua Kou Qiang Yi Xue Za Zhi; 2009 Apr; 44(4):227-31. PubMed ID: 19576004
[TBL] [Abstract][Full Text] [Related]
10. [SH3BP2 heterozygous mutation amplifies macrophage inflammatory responses to infection in a mouse model of cherubism].
Deckert M; Prod'Homme V
Med Sci (Paris); 2015; 31(6-7):589-91. PubMed ID: 26152156
[No Abstract] [Full Text] [Related]
11. Imatinib has minimal effects on inflammatory and osteopenic phenotypes in a murine cherubism model.
Mukai T; Akagi T; Hiramatsu Asano S; Tosa I; Ono M; Kittaka M; Ueki Y; Yahagi A; Iseki M; Oohashi T; Ishihara K; Morita Y
Oral Dis; 2023 Apr; 29(3):1089-1101. PubMed ID: 34743383
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the SH3BP2 gene mutation in cherubism.
Lee JY; Jung YS; Kim SA; Lee SH; Ahn SG; Yoon JH
Acta Med Okayama; 2008 Jun; 62(3):209-12. PubMed ID: 18596838
[TBL] [Abstract][Full Text] [Related]
13. The adapter 3BP2: how it plugs into leukocyte signaling.
Deckert M; Rottapel R
Adv Exp Med Biol; 2006; 584():107-14. PubMed ID: 16802602
[No Abstract] [Full Text] [Related]
14. Cherubism allele heterozygosity amplifies microbe-induced inflammatory responses in murine macrophages.
Prod'Homme V; Boyer L; Dubois N; Mallavialle A; Munro P; Mouska X; Coste I; Rottapel R; Tartare-Deckert S; Deckert M
J Clin Invest; 2015 Apr; 125(4):1396-400. PubMed ID: 25705883
[TBL] [Abstract][Full Text] [Related]
15. Novel nucleotide mutation leading to a recurrent amino acid alteration in SH3BP2 in a patient with cherubism.
Sangu N; Shimosato T; Inoda H; Shimada S; Shimojima K; Ando T; Yamamoto T
Congenit Anom (Kyoto); 2013 Dec; 53(4):166-9. PubMed ID: 24712477
[TBL] [Abstract][Full Text] [Related]
16. SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubism.
Lietman SA; Prescott NL; Hicks DG; Westra WH; Levine MA
Clin Orthop Relat Res; 2007 Jun; 459():22-7. PubMed ID: 17545756
[TBL] [Abstract][Full Text] [Related]
17. A novel mutation of the SH3BP2 gene in an aggressive case of cherubism.
Carvalho VM; Perdigão PF; Pimenta FJ; de Souza PE; Gomez RS; De Marco L
Oral Oncol; 2008 Feb; 44(2):153-5. PubMed ID: 17368082
[TBL] [Abstract][Full Text] [Related]
18. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice.
Ueki Y; Lin CY; Senoo M; Ebihara T; Agata N; Onji M; Saheki Y; Kawai T; Mukherjee PM; Reichenberger E; Olsen BR
Cell; 2007 Jan; 128(1):71-83. PubMed ID: 17218256
[TBL] [Abstract][Full Text] [Related]
19. The role of SH3BP2 in the pathophysiology of cherubism.
Reichenberger EJ; Levine MA; Olsen BR; Papadaki ME; Lietman SA
Orphanet J Rare Dis; 2012 May; 7 Suppl 1(Suppl 1):S5. PubMed ID: 22640988
[TBL] [Abstract][Full Text] [Related]
20. Rescue of a cherubism bone marrow stromal culture phenotype by reducing TGFβ signaling.
Liu Y; Sharma T; Chen IP; Reichenberger E; Ueki Y; Arif Y; Parisi D; Maye P
Bone; 2018 Jun; 111():28-35. PubMed ID: 29530719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
